IL36A and inflammatory bowel disease: Indeed, infliximab, an anti-TNF-α antibody, has shown remarkable efficacy in regulating inflammation in IBD patients; however, worsened stenosis of the intestinal tract can occur even after the induction of remission, which may involve IL-36α.